Treating AML (Acute Myeloid Leukemia)

Why an experienced center matters

Acute myeloid leukemia (AML) is an aggressive blood cancer that requires specialized, coordinated care. Outcomes are closely linked to the experience of the oncology team and its ability to manage the many subtypes and complications of the disease across the whole course of treatment.

Induction — achieving remission

Treatment usually begins with induction, whose goal is remission. This is delivered through chemotherapy, often using the standard "7+3" protocol. Targeted therapies may be added when specific genetic markers are found in the leukemic cells.

Consolidation — preventing relapse

Once remission is achieved, consolidation therapy aims to eliminate any remaining cancer cells. Standard consolidation uses high-dose chemotherapy or stem cell transplantation; patients in the intermediate- and high-risk groups typically proceed to transplantation.

The role of stem cell transplant

An allogeneic transplant — using healthy stem cells from a donor — is the main transplant type for AML and can offer a curative chance. The timing and decision to transplant depend on the AML subtype and the genetic risk classification, so donor searches often begin early.

Maintenance and follow-up

Maintenance therapy may follow consolidation to reduce the risk of relapse. Every plan is individualized to the disease and the patient, with close, ongoing monitoring to detect any recurrence as early as possible.

This article is for general information only and is not a substitute for professional medical advice. Always consult a qualified specialist about your individual condition.